![](https://investorshub.advfn.com/uicon/496411.png?cb=1505403973)
Friday, July 12, 2024 1:09:17 PM
Ilfeld's study design was good. The problem was the small sample size. If either arm had one or two heavy opioid users, that would skew the results.
It's important to note that opioid prescriptions typically instruct the patient to take the opioids only for "breakthrough pain." This study has a good design: the hypothesis was that, all else equal (including the use of tylenol and ice packs and opioids and anything else), the Arm that used the active device would take fewer opioid pills than the placebo Arm. It didn't happen. The opposite happened.
In research, all results tell the researcher something as long as the protocol wasn't compromised. What I think these results tell Ilfeld is that the sample size was too small and/or he included too many indications, some of which didn't respond as well to the ActiPatch. That, IMO, is the reason he started the SofPulse study halfway through the ActiPatch study with just three cherry-picked indications.
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM